# EDGAR Filing Document

**Accession Number:** 0001782805
**File Stem:** 0001104659-23-004743
**Filing Date:** 2023-1
**Character Count:** 12787
**Document Hash:** 294736ebee33a96ea7bbc8a3ca6b8684
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-004743.hdr.sgml**: 20230118

**ACCESSION NUMBER**: 0001104659-23-004743

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230113

**FILED AS OF DATE**: 20230118

**DATE AS OF CHANGE**: 20230118

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Mandelia Ashish
- **CENTRAL INDEX KEY:** 0001782805

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38129
- **FILM NUMBER:** 23535709

**MAIL ADDRESS:**
- **STREET 1:** 840 MEMORIAL DRIVE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mersana Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001442836
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 840 MEMORIAL DRIVE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 617-498-0020

**MAIL ADDRESS:**
- **STREET 1:** 840 MEMORIAL DRIVE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MERSANA THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20080813

## Ex-24

**Exhibit 24**

**POWER OF ATTORNEY**

The undersigned hereby constitutes and appoints each of Anna Protopapas, Brian DeSchuytner, Alejandra Carvajal and Brigitte Eichner of Mersana Therapeutics, Inc. (the "Company"), signing individually, with full power of substitution, as the undersigned's true and lawful attorneys-in-fact and agents to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) prepare,
 execute in the undersigned's name and on the undersigned's behalf, and submit
 to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including
 amendments thereto, and any other documents necessary or appropriate to obtain codes and
 passwords enabling the undersigned to make electronic filings with the SEC of reports required
 by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation
 of the SEC;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) prepare,
 execute in the undersigned's name and on the undersigned's behalf, and submit
 to the SEC, in the undersigned's capacity as officer, director or beneficial owner
 of more than 10%
of a registered class of securities of the Company of the Company, Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities
Exchange Act of 1934, as amended, and the rules thereunder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) do
 and perform any and all acts for and on behalf of the undersigned that may be necessary or
 desirable to complete and execute any such Form ID or Forms 3, 4, or 5, complete and execute
 any amendment or amendments thereto, and timely file such form with the SEC and any stock
 exchange or similar authority; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) take
 any other action of any type whatsoever in connection with the foregoing that, in the opinion
 of such attorney-in-fact, may be of benefit to, in the best interest of, or legally
 required by, the undersigned, it being understood that the documents executed by such attorney-in-fact
 on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and
 shall contain such terms and conditions as such attorney-in-fact may approve in such
 attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company.

<br> [*Remainder of page intentionally left blank*]

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 8th day of April, 2022.

---

| |
|:---|
| /s/ Ashish Mandelia |
| Ashish Mandelia |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Mandelia Ashish<br><sub>(Last) (First) (Middle)</sub><br>C/O MERSANA THERAPEUTICS, INC.<br>840 MEMORIAL DRIVE<br><sub>(Street)</sub><br>CAMBRIDGE, MA 02139<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-13 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_VP, Controller_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Mersana Therapeutics, Inc. [ MRSN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-01-14 |  | M<sup>(1)</sup> |  | 4784 | A | $0 | 11842<sup>(2)</sup> | D |  |
| Common Stock | 2023-01-15 |  | M<sup>(3)</sup> |  | 4519 | A | $0 | 16361 | D |  |
| Common Stock | 2023-01-15 |  | M<sup>(4)</sup> |  | 833 | A | $0 | 17194 | D |  |
| Common Stock | 2023-01-17 |  | S<sup>(5)</sup> |  | 3575 | D | 5.74<sup>(6)</sup> | 13619 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock option (right to buy) | $6.06 | 2023-01-13 |  | A |  | 47625 |  | <sup>(7)</sup> | 2033-01-12 | Common Stock | 47625 | $0 | 47625 | D |  |
| Restricted stock unit | <sup>(8)</sup> | 2023-01-13 |  | A |  | 10583 |  | <sup>(9)</sup> | <sup>(9)</sup> | Common Stock | 10583 | $0 | 10583 | D |  |
| Restricted stock unit | <sup>(8)</sup> | 2023-01-14 |  | M |  |  | 4784 | <sup>(10)</sup> | <sup>(10)</sup> | Common Stock | 4784 | $0 | 14349 | D |  |
| Restricted stock unit | <sup>(8)</sup> | 2023-01-15 |  | M |  |  | 4519 | <sup>(11)</sup> | <sup>(11)</sup> | Common Stock | 4519 | $0 | 9038 | D |  |
| Restricted stock unit | <sup>(8)</sup> | 2023-01-15 |  | M |  |  | 833 | <sup>(12)</sup> | <sup>(12)</sup> | Common Stock | 833 | $0 | 833 | D |  |

---

### Footnotes:

(1) Represents shares of common stock received upon the vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 14, 2022.

(2) Includes 3,687 shares of common stock acquired on December 30, 2022 by the Reporting Person through the Issuer's employee stock purchase plan.

(3) Represents shares of common stock received upon the vesting of a portion of the RSUs awarded to the Reporting Person on January 15, 2021.

(4) Represents shares of common stock received upon the vesting of a portion of the RSUs awarded to the Reporting Person on January 15, 2020.

(5) Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs reported above. These sales were mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to sell a number of shares of common stock needed to satisfy his tax withholding obligations and does not represent a discretionary trade by the Reporting Person.

(6) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $5.74 to $5.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

(7) The option shall vest in equal quarterly installments over four years from the date of grant.

(8) Each RSU represents the contingent right to receive one share of common stock of the Issuer.

(9) The RSUs shall vest in equal annual installments over four years from the date of grant.

(10) 25% of the total number of RSUs granted vested on January 14, 2023, and the remainder shall vest thereafter in equal annual installments over the next three years.

(11) 25% of the total number of RSUs granted vested on January 15, 2023, and the remainder shall vest thereafter in equal annual installments over the next two years.

(12) 25% of the total number of RSUs granted vested on January 15, 2023, and the remainder shall vest on January 15, 2024.

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/Alejandra Carvajal, as attorney-in-fact  
**Date:** 2023-01-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**